secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001628280-24-049281
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead reports FY2024 net loss $599.5M; inks Sarepta deal, files plozasiran NDA
--------------------------------------------------------------------------------

- Net loss of $599.5M (-$5.00 diluted EPS) vs $205.3M loss (-$1.92) in FY2023.
- Revenue fell to $3.55M from $240.7M, primarily due to lower collaboration revenue.
- Signed licensing deal with Sarepta: $825M upfront ($500M cash, $325M equity), plus $250M over 5 years.
- Closed $500M senior secured credit facility with Sixth Street; $400M funded at close.
- Submitted NDA for plozasiran (FCS) and received Breakthrough Therapy designation from FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828024049281/0001628280-24-049281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828024049281/arwr-20241126.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-049281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer